Ascletis gets Chinese drug regulator nod to start trial of oral COVID therapy
Ascletis Pharma (ASCLF) said China's National Medical Products Administration ((NMPA)) approved its investigational new drug ((IND)) application for starting a trial of oral drug ASC11...
Source: seekingalpha.com